Up to 60% of PDA patients have loss‐of‐function TGFBR2 or SMAD4 mutations (Waddell et al, 2015), and importantly, these patients have significantly shorter survival and a worse prognosis after surgery (Tascilar et al, 2001). This evidence concerns the gene TGFBR2 and Patent ductus arteriosus.